Publications are part of the bigger communication plan which also covers PR, scientific dialog, promotion, training, and internal communications. Writing publications should follow an overall strategy for the compound or therapeutic area. They are necessary for further steps like having promotional material, HTA submissions, scientific/medical dialog, etc.
They should not be an afterthought or seen as a pure incentive.

In this episode, Jenny Devenport and I talk about these publications as critical part of the scientific process We also cover how creating these helps establishing credibility with various stakeholders.

We also discuss the following points:

What is a secondary paper?
What is its typical content?
Where is the content coming from?
A secondary paper is a paper you do once you are done with your primary paper. I've been working on this for a long time and always have fun doing it.

Together with Benjamin, we discuss the following points:

Feeling comfortable does not lead to growth.

But why do most people stay in their comfort zone?
Are your own expectations holding you back?

In this episode, I am talking about the reasons why people stay in their comfort zones and always choose the “safe side”. And why choosing this hinders you from your personal and career growth.

I am really passionate about leadership and Claude Petit is also passionate about building leaders and being an effective leader. Together, we will share with you how to become a statistical leader and how to build such an organization.

So stay tuned!

What is a pharmacometrician?
What does the training of a pharmacometrician look like?

In my career, my experience of working with pharmacometricians was very limited because I spent most of my time working more on the later phases; and the contact with people in that space of the industry is not that big, that's why I found this episode really helpful. If you don't have a clue what they do then stay tuned for this episode.

What can go wrong with network meta-analyses?

You often have multiple endpoints but these are not collected consistently across all the studies included in the NMA. How do you deal with this?

Even with the same variables assessed over studies, they might be collected at different time points. This often has an effect on both efficacy and safety results. What do you do?

Your placebo treatment might change over time and consequently your placebo response. Often placebo plays a crucial part in your network, but can you really pool all your placebo arms? The patient population differs between studies and hence between treatments. How do you control this bias?

The pool of relevant treatments differs across countries when using network meta-analyses for HTA submissions. Should you adapt your NMA for each country's submission?

You’re not submitting all your HTA dossiers at once and thus the literature search needs to be updated repeatedly hence you input data into the NMA. How big are the differences and how long will it take to update everything (and what will it cost?)?

In today's episode, I am the interviewee, and Jenny is the one asking the questions. We are talking about how training in launch and commercialization can be a super weapon, what its role is, and how can this be developed and administered for non-statisticians.

We also talk about the following interesting points:

The world has changed, and it will not turn back to what is used to be before the pandemic. This comes on top of other trends, like the increased use of data across all aspects of data. The hunger for talent in the data science space has dramatically increased, and it is not only coming from the Apples, Googles, and Amazons.

Other trends are the increase in prices, the shifts in motivations of employees, and the debate about what really makes people join and stay at companies.

I first became aware of these sources for real-world evidence some years ago, and I tried to get an expert on this topic so often, but unfortunately no one would speak with me. Then finally someone agreed when they found out what country my research was being conducted in-the Scandinavian Union! You might be wondering why we need data from such a unique place as Scandinavia? Stay tuned because you'll find out soon enough… This region provides us statisticians everything we could hope: perfect measurements plus high-quality counts.

Is a board of directors essential for everyone?
Is it necessary for it to come from within your company?

This episode is all about career advise. Together with Heather, we talk about having your personal board of directors and how could this concept help you have a career advancement overtime.